Novo Nordisk A/S Stock Forecast:
According to the forecasts of three analysts, the average target price for Novo Nordisk A/S stock over the next 12 months is USD 175.00. The average analyst rating for the stock is Strong Buy. Stock Target Advisor, based on its own analysis, also has a bullish outlook for Novo Nordisk A/S, considering 13 positive signals and 5 negative signals. As of the last closing, the stock price of Novo Nordisk A/S was USD 157.07. Over the past week, the stock price has decreased by -1.48%, over the past month by -0.62%, and over the last year, it has shown an increase of +44.06%.
Novo Nordisk News:
An analysis of U.S. pharmacy claims has shed light on the challenges faced by patients prescribed popular weight-loss drugs such as Novo Nordisk‘s Wegovy. The findings reveal that only about one-third of patients prescribed Wegovy were still taking the medication after a year. Moreover, the analysis indicates a significant rise in total healthcare costs for these patients, painting a complex picture of the drug’s impact on both patient adherence and financial burden.
The analysis, which was shared with Reuters, compared the annual healthcare costs of patients prior to taking Wegovy or a similar weight-loss drug and those who did not take any such medication. Prior to starting the medication, the average annual cost of overall care for patients was $12,371. However, after initiating Wegovy, the full-year cost skyrocketed by 59% to an average of $19,657. In contrast, the costs for the control group of patients not taking these drugs decreased by 4% over the same period.
These findings raise important questions about the effectiveness and sustainability of weight-loss drugs like Wegovy. While such medications have shown promise in aiding weight reduction, their long-term usage and impact on patient adherence remain crucial factors to consider.
FA Score (Fundamental Analysis):
The fundamental analysis of Novo Nordisk is “Bullish” with a FA score of 7.2 out of 10, where 0 is very bearish and 10 is very bullish.
